2006, Número S1
<< Anterior Siguiente >>
Ann Hepatol 2006; 5 (S1)
Module lX
Treatment of chronic hepatitis C infection in cirrhotic patients
Dagher L
Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 36-39
Archivo PDF: 48.42 Kb.
FRAGMENTO
Sin resumen
REFERENCIAS (EN ESTE ARTÍCULO)
World Health Organization. Weekly epidemiological record 1999; 74: 421-8.
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
Planas R, Balleste B, Alvarez MA, Rivera M, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 2004; 40: 823-30.
Everson G. Management of cirrhosis due to chronic hepatitis C. Journal of Hepatology 2005; 42: S65-S74.
Wiesner R, Sorell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Liver Transpl 2003; 9: S1-S9.
Murray K, Carithers R. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.
Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peg-interferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975-82.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
Burroughs AK, Groszmann R, Bosch J, Grace N, Garcia Tsao G, Carcia-Pagan JC, et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002; 50: 425-7.
Ratti L, Pozzi M, Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis: Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Article in Press. Digestive and Liver Disease.
Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.
Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trial 2004; 25: 472-92.
Afdhal N, Freilich B, Levine R, Black M, Brown R, Monsour H, et al. Colchicine versus peg-interferon long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 2004; 40: 238A.
Curry M, Cardenas A, Afdhal NH. Effect of maintenance Peginterferon therapy on portal hypertension and its complications: results from the COPILOT study. Program and abstracts of the 40th Annual Meeting of the European Association for the Study of the Liver; April 13–17, 2005; Paris, France. Abstract 95.
Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidencebased approach. Current Pharmacological Design 2004; 10: 2123-30.
Shiratori Y, Ito Y, Yoyosuka O, Imazeki F, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14.
Patheodoridis GV, Papadimitropoulos V, Hadzyiannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a metaanalysis. Aliment Pharmacol Ther 2001; 15: 689-98.